newsfilter
← Latest News
PR Newswire·

AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's Disease

TAIPEI, March 10, 2023 /PRNewswire/ -- AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. ((Avenue, NASDAQ:ATXI) for the development and commercialization of